- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04511871
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single arm, open label, dose escalation clinical study to evaluate the safety and preliminary therapeutic efficacy of CCT303-406 cells in adult subjects with HER2 positive relapsed or refractory stage IV metastatic solid tumors.
Subjects that meet inclusion criteria with positive biopsy HER2 (IHC 3+ in ≥50% tumor cells) will receive CCT303-406 according to the 3+3 dose escalation design.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Yuhong Zhou, M.D.
- Phone Number: 2968 +86-21-64041990
- Email: zhou.yuhong@zs-hospital.sh.cn
Study Contact Backup
- Name: Wei Zhang, Ph.D.
- Phone Number: +86-17721010028
- Email: wzhang@perhum.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Zhongshan Hospital affiliated to Fudan University
-
Contact:
- Yuhong Zhou, M.D.
- Phone Number: 2968 +86-21-64041990
- Email: zhou.yuhong@zs-hospital.sh.cn
-
Contact:
- Wei Zhang, Ph.D.
- Phone Number: +86-17721010028
- Email: wzhang@perhum.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with willingness to be in the study and follow all study procedures, and capable of providing informed consent
- Male or female aged 18-70 years
- Patients with stage IV (according to the 8th edition of AJCC) advanced solid tumor malignancies that have failed standard treatment of relapsed or difficult-to-treat solid tumors confirmed by histology or cytology
- At least one measurable lesion, i.e. the length of non-lymph node lesions examined according to CT cross-sectional scanning or magnetic resonance imaging (MRI), or the short diameter of the lymph node lesions is ≥15 mm according to RECIST 1.1
- Tumors with HER2 IHC 3+ in≥50% of all tumor cells as determined by IHC according to the Breast Cancer HER2 Testing (2019 edition) and the Gastric Cancer HER2 Testing (2016 edition); For HER2 IHC 3+ tumors other than gastric and breast cancers, FISH is required to confirm HER2 expression; For relapsed patients after HER2-targeted therapies, biopsy and IHC are required to confirm HER2 expression per enrollment criteria.
- ECOG Performance Status 0-1
- Expected survival greater than 12 weeks
Adequate organ and hematopoietic system functions to meet the following requirements:
- Hemoglobin (HGB) s 90 g/L, no blood transfusions within two weeks;
- White blood cell (WBC) count≥2.5×109/L
- Absolute Neutrophil Count (ANC) ≥1.5 x 109/L
- Platelet (PLT) count ≥80-109/L
- Total bilirubin (TBIL) ≤3.0ng/dL or ≤5 ULN
- ALT and AST ≤5 ULN; for liver metastasis, ALT and AST ≤5 ULN
- Creatinine (Cr) ≤1.5 x ULN; or creatinine removal rate (CrCl) ≥50 mL/min
- LVEF≥50%
- Serum troponin T <0.03 ng/mL
- PT: INR < 1.7 or extended PT to normal value < 4s
- Normal language, recognition and consciousness assessed by investigator during screening phase
- Capable of receiving treatment and follow-up, including treatment in the clinical center;
- Female subjects of childbearing age must take acceptable measures to minimize the likelihood of pregnancy during the trial. The results of serum or urine pregnancy test must be negative
- Female subjects must not be in the lactation period.
Exclusion Criteria:
- Females with pregnancy or in lactation period
- Patients with active hepatitis B, or active hepatitis C
- HIV positive
- Other active infections of clinical significance
- Patients receiving in situ surgery within 3 months
Patients with the following previous or accompanying diseases:
• Patients diagnosed as severe autoimmune diseases that require long term (more than 2 months) treatment with systemic immunosuppressants (steroids), or diseases with immune-mediated symptoms, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), and autoimmune vasculitis
- Patients with ≥Grade 2 peripheral neuronal diseases (according to NCI-CTCAE v5.0)
- Patients with any mental illness, including dementia, mental changes, which may cause difficulties understanding the informed consent and related questionnaires
- Patients with serious uncontrollable diseases, which may interfere with the therapies in this study
- Patients with other active malignancies in the past 5 years excluding those with completely cured basal or squamous skin cancers, superficial bladder cancers or primary breast cancers without need of follow-up treatment
- Patients receiving systemic steroids or steroid inhalants
- Patients who have received tumor immunotherapy (including monoclonal antibody or cell therapy) in the past 4 weeks
- Patients allergic to immunotherapies or related drugs
- Patients with metastatic lesions in meninges or central nervous system, or clear evidence of central nervous system diseases with continous significant symptoms in the last 6 months
- Patients with NYHA class II heart failure, or hypertension incontrollable by standard care, or medical history of myocarditis, or heart attack within a year
- Patients who have received or are going to receive organ transplantation
- Patients with active bleeding
- Patients with incontrollable pleural or abdominal fluid that needs clinical treatment or intervention
- Patients having undergone major surgery within 4 weeks or have not fully recovered from prior surgery
- Patients that have received radiotherapy within 4 weeks, excluding those who received local irradiation for the peripheral bone metastatic lesions for more than 2 weeks, and recovered from all acute toxicities of radiotherapy
- Patients that have received anthracyclines within 8 weeks
- Patients as determined by the investigators to be inappropriate for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CCT303-406
To determine the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of CCT303-406 cell therapy in patients with HER2-positive (IHC 3+ in ≥50% tumor cells) relapsed or refractory solid tumors. Dose cohorts:
|
Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406.
Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MTD: to determine the maximum tolerated dose of CCT303-406
Time Frame: 28 days following infusion
|
To assess the DLT (dose limiting toxicities) attributed to CCT303-406 per cohort and determine the RP2D (recommended phase 2 dose).
|
28 days following infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR (overall response rate): Proportion of subjects with the best overall response (BOR)
Time Frame: Up to 52 weeks
|
Best overall response (BOR) of subjects with PR (partial response) and CR (complete response) as determined by local investigator using RECIST 1.1
|
Up to 52 weeks
|
12 month survival rate
Time Frame: Up to 52 weeks
|
The proportion of living subjects within 52 weeks of infusion
|
Up to 52 weeks
|
DCR: Disease control rate
Time Frame: Up to 52 weeks
|
The proportion of subjects with CR (complete response), PR (partial response) or SD (stable disease lasting over 6 months) as determined by local investigator using RECIST 1.1.
|
Up to 52 weeks
|
DOR: Duration of reponse
Time Frame: Up to 52 weeks
|
The duration of time from record of response to first progression of disease as determined by RECIST 1.1 or death date not relevant to disease progression
|
Up to 52 weeks
|
PFS: Progression free survival
Time Frame: Up to 52 weeks
|
The time of disease progression by RECIST 1.1 or death since cell infusion
|
Up to 52 weeks
|
AE: Adverse Events
Time Frame: Up to 52 weeks
|
The incidence, severity and duration of AE, TEAE and SAE as determined by NCI-CTCAE v5.0
|
Up to 52 weeks
|
The expansion over time of genetically modified CCT303-406 cells in the peripheral blood as determined by QPCR (copies/ug gDNA)
Time Frame: Up to 52 weeks
|
PK: Pharmacokinetics
|
Up to 52 weeks
|
The persistence over time of genetically modified CCT303-406 cells in the peripheral blood as determined by Flow Cytometry (% CAR + cells)
Time Frame: Up to 52 weeks
|
PK: Pharmacokinetics
|
Up to 52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploration of target-efficacy correlation
Time Frame: Up to 52 weeks
|
The correlation between levels of HER2 expression and ORR
|
Up to 52 weeks
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CCT303-406-mST01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
-
Advenchen Laboratories, LLCActive, not recruitingLeiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue SarcomaUnited States, United Kingdom, Spain, China, Italy
Clinical Trials on CCT303-406
-
Debiopharm International SACompletedLymphoma | Cancer | Solid Tumors | MalignancyUnited States
-
CytRxCompletedB-Cell Chronic Lymphocytic LeukemiaUnited States
-
CytRxCompletedHormone Refractory Prostate CancerUnited States
-
CytRxCompletedChronic Myeloid Leukemia | Acute Lymphocytic LeukemiaUnited States, Israel, Germany
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Tumor | Tumors Metastatic to Brain | Adult Anaplastic OligoastrocytomaUnited States
-
I.R.C.C.S. Fondazione Santa LuciaCompleted
-
Ascenta TherapeuticsThe Leukemia and Lymphoma SocietyTerminated
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Not yet recruitingHead and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III... and other conditions